
CONMED Corporation CNMD
$ 42.12
3.97%
Quarterly report 2025-Q3
added 11-06-2025
CONMED Corporation Book Value 2011-2026 | CNMD
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value CONMED Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 963 M | 834 M | 746 M | 785 M | 709 M | 710 M | 662 M | 631 M | 581 M | 585 M | 581 M | 606 M | 607 M | 573 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 963 M | 573 M | 684 M |
Quarterly Book Value CONMED Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.01 B | 1 B | 978 M | 933 M | 882 M | 855 M | 796 M | 780 M | 752 M | 746 M | 716 M | - | 790 M | 785 M | 756 M | 744 M | 726 M | 709 M | 709 M | 709 M | 709 M | 710 M | 710 M | 710 M | 710 M | 662 M | 662 M | 662 M | 662 M | 631 M | 631 M | 631 M | 631 M | 581 M | 581 M | 581 M | 581 M | 585 M | 585 M | 585 M | 585 M | 581 M | 581 M | 581 M | 581 M | 606 M | 606 M | 606 M | 606 M | 607 M | 607 M | 607 M | 607 M | 573 M | 573 M | 573 M | 573 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.01 B | 573 M | 683 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AxoGen
AXGN
|
104 M | $ 31.63 | 2.03 % | $ 1.4 B | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Boston Scientific Corporation
BSX
|
39.4 B | $ 95.41 | 0.76 % | $ 140 B | ||
|
Abiomed
ABMD
|
1.33 B | - | - | $ 17.2 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
776 M | $ 21.25 | 2.36 % | $ 3.04 B | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
26.9 M | $ 3.6 | 2.86 % | $ 125 M | ||
|
Cognyte Software Ltd.
CGNT
|
217 M | $ 9.15 | 2.81 % | $ 657 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 320.95 | 5.1 % | $ 9.06 B | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 50.6 | 5.18 % | $ 7.54 K | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 3.48 | 2.35 % | $ 130 M | ||
|
Abbott Laboratories
ABT
|
81.4 B | $ 126.37 | 1.76 % | $ 220 B | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
43.2 M | $ 28.03 | 2.34 % | $ 237 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
704 M | $ 15.27 | 3.18 % | $ 1.21 B | ||
|
IRadimed Corporation
IRMD
|
86.8 M | $ 98.11 | 2.73 % | $ 1.24 B | ||
|
Align Technology
ALGN
|
3.85 B | $ 160.18 | 2.66 % | $ 12 B | ||
|
OrthoPediatrics Corp.
KIDS
|
355 M | $ 18.13 | 3.22 % | $ 418 M | ||
|
Accuray Incorporated
ARAY
|
81.2 M | $ 0.89 | 4.38 % | $ 91.5 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
25.4 M | $ 14.34 | 2.21 % | $ 388 M | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.52 | 0.03 % | $ 121 M | ||
|
LivaNova PLC
LIVN
|
1.32 B | $ 63.29 | 4.37 % | $ 3.43 B | ||
|
LENSAR
LNSR
|
18.6 M | $ 11.32 | -2.5 % | $ 130 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
IRIDEX Corporation
IRIX
|
9.52 M | $ 1.21 | 3.42 % | $ 19.5 M | ||
|
Globus Medical
GMED
|
4.18 B | $ 90.81 | 4.02 % | $ 12.3 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 12.56 | 4.58 % | $ 967 M | ||
|
Aziyo Biologics
AZYO
|
-38.6 M | - | 1.37 % | $ 20.5 M | ||
|
Establishment Labs Holdings
ESTA
|
53.1 M | $ 65.25 | -5.21 % | $ 1.84 B |